Comparative Effects of Sulforaphane and Allyl Isothiocyanate on 3T3-L1 Adipogenesis

Sakuma, Satoru; Yasuda, Kana; Kitahara, Risa; Tsujimoto, Kaho; Yamashita, Kishiko; Hoshino, Naohiro; Fujimoto, Yohko; Okuhira, Keiichiro

doi:https://doi.org/10.1155/2022/8705163

Journal of Nutrition and Metabolism

On this page

Abstract Introduction Materials and Methods Results Discussion Conclusion Data Availability Conflicts of Interest Acknowledgments References Copyright Related Articles

Research Article | Open Access

Volume 2022 | Article ID 8705163 | https://doi.org/10.1155/2022/8705163

Comparative Effects of Sulforaphane and Allyl Isothiocyanate on 3T3-L1 Adipogenesis

Satoru Sakuma,¹Kana Yasuda,¹Risa Kitahara,¹Kaho Tsujimoto,¹Kishiko Yamashita,¹Naohiro Hoshino,¹Yohko Fujimoto,¹and Keiichiro Okuhira¹

Academic Editor: Eric Gumpricht

Received16 Aug 2021

Accepted20 Dec 2021

Published19 Jan 2022

Abstract

Sulforaphane and allyl isothiocyanate, naturally occurring isothiocyanates, have been reported to inhibit adipocyte differentiation, but little is known about how they compare in terms of their potency and mechanism of action. In the present study, we compared the effects of sulforaphane and allyl isothiocyanate on the differentiation of 3T3-L1 preadipocytes. A mixture of insulin, dexamethasone, and 3-isobutyl-1-methylxanthine was used to establish a differentiation medium. We found that, at a concentration as low as one-tenth that of allyl isothiocyanate, sulforaphane reduced triacylglycerol levels, lipid-filled adipocyte quantity, and mRNA and protein levels of CCAAT-enhancer-binding protein α (C/EBPα) and peroxisome proliferator-activated receptor γ (PPARγ). These results suggested that sulforaphane may be a more potent adipocyte differentiation inhibitor than allyl isothiocyanate. Our results may provide insight into possible strategies for the prevention of obesity and related conditions.

1. Introduction

Obesity is a serious health problem worldwide, increasing the morbidity and mortality rates associated with several acute and chronic diseases, such as dyslipidemia, hypertension, type-2 diabetes, and cardiovascular disease [1, 2]. Obesity is characterized by increases in adipocyte quantity (hyperplasia) and size (hypertrophy) [3], which are regulated by genetic, metabolic, and nutritional factors [4]. Therefore, deciphering the mechanism by which certain nutrients affect adipocyte differentiation is important for preventing obesity and related conditions.

Isothiocyanates (ITCs) include both naturally occurring substances, such as sulforaphane and allyl isothiocyanate, and synthetically produced substances, such as fluorescein isothiocyanate and p-bromophenyl isothiocyanate. ITCs exhibit a wide range of known biological effects [5, 6]. These effects are derived from the reactivity of the ITC group (−NCS) and from the physicochemical properties of the non-ITC portion of the molecule, such as lipophilicity, shape, size, and rigidity. The reactivity of the ITC group determines the ability of the ITC to react with the functional groups of small biochemical molecules or biopolymers [7], and the physicochemical properties of the rest of the molecule may be responsible for its bioavailability in different cell compartments and tissues [8].

Sulforaphane (Figure 1) is found in cruciferous vegetables such as broccoli sprouts, Brussels sprouts, and cabbage. Allyl isothiocyanate (Figure 1) is known to be responsible for the characteristic pungent aroma of some cruciferous vegetables, including radishes and horse radishes. Both of these are naturally occurring ITCs repress adipogenesis [9–11]. However, with the exception of their ITC moieties, the pharmacological differences caused by their distinct structures—the sulfinyl groups in sulforaphane and the allyl groups in allyl isothiocyanate—have not been investigated.

The present study investigated the comparative effects of sulforaphane and allyl isothiocyanate on triacylglycerol (TG) levels, lipid-filled adipocyte quantity, and mRNA and protein expression levels of CCAAT-enhancer-binding protein α (C/EBPα) and peroxisome proliferator-activated receptor γ (PPARγ) during the differentiation of 3T3-L1 preadipocytes into mature adipocytes.

2. Materials and Methods

2.1. Materials

Mouse 3T3-L1 preadipocytes were obtained from the European Collection of Cell Cultures (Wiltshire, UK). The Transcriptor First Strand cDNA Synthesis Kit and LightCycler FirstStart DNA Master^plus SYBR Green reagent were obtained from Roche Diagnostics (Indianapolis, IN, USA). TRIzol reagent and the primers for β-actin, PPARγ, and C/EBPα were purchased from Invitrogen (Carlsbad, CA, USA). Rabbit polyclonal anti-human β-actin, PPARγ, and C/EBPα antibodies and goat HRP-linked anti-rabbit IgG antibody were obtained from Cell Signaling Technology, Beverly, MA, U.S.A. Sulforaphane, allyl isothiocyanate, and a protease inhibitor cocktail were obtained from Sigma Chemical Co. (St. Louis, MO, USA). The Triglyceride E-test Wako kit was obtained from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). The Lipid Droplets Fluorescence Assay Kit was obtained from Cayman Chemical Co. (Ann Arbor, MI, USA). All other reagents used were of analytical grade.

2.2. Cell Culture

Mouse 3T3-L1 preadipocytes were cultured in Dulbecco’s Modified Eagle’s Medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin (growth medium) at 37°C in a humidified atmosphere of 5% CO₂/95% air. Cell differentiation was induced according to the protocol obtained from the European Collection of Cell Cultures. The procedure was initiated 2 d after the cells reached confluence. The cells were cultured for 3 d in differentiation medium (DM) containing 0.25 µM dexamethasone, 0.5 mM 3-isobutyl-1-methylxanthine (IBMX), and 1 µg/mL insulin. Next, the cells were cultured for 2 d in maturation medium containing 1 µg/mL insulin. Finally, they were cultured in growth medium again for 2 d. ITC treatment, Oil Red O staining, and the determination of TG levels, lipid-filled adipocyte numbers, and mRNA and protein expression levels of PPARγ and C/EBPα were performed according to our previously reported methods [12–14].

2.3. Treatment with Sulforaphane or Allyl Isothiocyanate

Sulforaphane and allyl isothiocyanate were prepared in dimethyl sulfoxide (Me₂SO) and added to the growth, differentiation, and maturation media on day 3 (when dexamethasone, IBMX, and insulin were added). The Me₂SO concentration was maintained at 0.25% of the total volume of the medium. Preliminary experiments demonstrated no significant effects of 0.25% Me₂SO on cell differentiation.

2.4. Oil Red O Staining

The cells were fixed in 4% formaldehyde phosphate buffer (pH 7.4) for 1 h, rinsed with water, and stained with 0.3% Oil Red O dye for 1 h. After washing again with water, the cells were observed under a microscope at 10 × 20 magnification.

2.5. Quantification of Mature Adipocytes

Mature adipocytes were quantified using the Lipid Droplets Fluorescence Assay Kit and flow cytometry. The cells were trypsinized carefully and centrifuged at 200 ×g for 5 min at 4°C. The cell pellet was resuspended, fixed, and stained with the lipophilic fluorescent dye Nile Red according to the manufacturer’s instructions. The samples were then analyzed using a BD FACSAria III flow cytometer (Becton Dickinson, Basel, Switzerland). After excitation with a 488 nm argon ion laser source, Nile Red fluorescence was measured on the FL2 (FITC-A) emission channel through a 585 ± 21 nm bandpass filter. Using a forward scatter/side scatter representation, the P1 region was defined to exclude cellular debris. A P2 selection window was defined as the area with high FL2 (FITC-A) values, representing mature adipocytes in the FL2 (FITC-A)/cell count blot of the P1 population, as described by Sottile and Seuwen [15]. Data analysis was performed using BD FACSDiva software (ver. 8.0, Becton Dickinson, Franklin Lakes, NJ, USA). For each sample, 20,000 events were recorded, and results were expressed as the percentage of cells in the P2 region.

2.6. Determination of TG Levels

The cells were harvested by scraping them from the culture dishes into a lysis buffer of 1% Triton-X100, 150 mM NaCl, 4 mM ethylenediaminetetraacetic acid, and 20 mM Tris-HCl (pH 7.4) containing a protease inhibitor cocktail. Cells were lysed completely using a horn-type sonicator. TG level, a lipid accumulation index, was determined using the Triglyceride E-test Wako kit after protein level normalization and was expressed as TG content (µg/mg protein).

2.7. Determination of the mRNA Expression Levels of β-actin, PPARγ, and C/Ebpα

At day 5, untreated cells were used as a control. Cells treated with sulforaphane or allyl isothiocyanate were washed with ice-cold phosphate-buffered saline. Total cellular RNA was extracted using TRIzol reagent, and 1 μg of total RNA was reverse transcribed into cDNA using the Transcriptor First Strand cDNA Synthesis Kit. The concentration and quality of the purified total RNA were determined spectrophotometrically at 260 nm. The ratio of optical density at 260 nm to that at 280 nm was also calculated. Next, mRNA expression was determined by real-time reverse transcription polymerase chain reaction using the SsoAdvanced^TM SYBR® Green Supermix (Bio-Rad, Hercules, CA, USA) reagent and a CFX Connect™ instrument (Bio-Rad). The results were expressed as the target mRNA level relative to that of β-actin mRNA, and the values obtained in the presence or absence of the drugs were expressed relative to the values associated with exposure to the DM alone.

The primers used were as follows: β-actin, 5′-ACACCCCAGCCATGTACG-3′ and 5′-TGGTGGTGAAGCTGTAGCC-3′, PPARγ, 5′-GTGAAGCCCATCGAGGACA-3′ and 5′-TGGAGCACCTTGGCGAACA-3′, and C/EBPα, 5′-ATGGTTTCGGGTCGCTGGAT-3′ and 5′-CCACGGCCTGACTCCCTCAT-3′.

2.8. Determination of the Protein Expression Levels of β-actin, PPARγ, and C/Ebpα

Untreated or sulforaphane or allyl isothiocyanate-treated 3T3-L1 cells up to day 5 were washed with ice-cold PBS and lysed. An equal volume of solubilization buffer (20% glycerol, 4% SDS, 2% 2-mercaptoethanol, 125 mM Tris/HCl, pH 6.8) was added and the mixture was boiled for 10 min. Cell lysates were analyzed using a 7.5% polyacrylamide gel. Proteins were transferred to nitrocellulose membranes by electroblotting, and the membranes were incubated overnight in TBS-T (0.14 M NaCl, 20 mM Tris, 0.1% Tween 20, pH 7.4) containing their respective primary antibodies (β-actin, PPARγ, and C/EBPα antibodies) and 3% skimmed milk powder. The membranes were incubated overnight. After incubation, the membranes were incubated with secondary goat HRP-conjugated anti-rabbit IgG antibody for 1 h, followed by Amersham ECL Western blotting detection reagent (Cytiva, Marlborough, MA, U.S.A.).

2.9. Statistical Analysis

The results are expressed as the mean ± standard error. Significant differences in data between the two groups were assessed using Student’s t-test, and differences between multiple groups were assessed using one-way analysis of variance followed by Scheffé’s multiple range test. Differences were considered statistically significant at .

3. Results

3.1. Effects of Sulforaphane and Allyl Isothiocyanate on 3T3-L1 Cell Differentiation

Figure 2 displays the effects of sulforaphane and allyl isothiocyanate on TG accumulation in 3T3-L1 adipocytes. The TG level of DM-cultured cells was approximately 8 times higher than that of the control cells. Sulforaphane decreased TG content in a concentration-dependent manner, with concentrations of 2–10 µM inducing 28%–74% reductions. Allyl isothiocyanate induced 32%–73% decreases in TG content at concentrations of 25–100 µM, at least 10 times the concentrations of sulforaphane required for the same effect. A 50 µM concentration of GW9662 [16], a PPARγ antagonist, reduces TG accumulation by 66%. Thus, allyl isothiocyanate suppressed TG content at nearly the same rate as GW9662, while sulforaphane’s inhibitory effect was much stronger. As shown in Figures 3 and 4, the DM-cultured cells exhibited larger quantities of Oil Red O-stained cells (Figure 3) and lipid-filled adipocytes (Figure 4) than the control cells. Compared to cells that were cultured in DM alone, DM-cultured cells treated with 2, 5, or 10 µM sulforaphane exhibited a concentration-dependent reduction in fat droplet quantity (Figure 3(a)) and a significant decrease—48%, 74%, and 86%, respectively—in the quantity of lipid-filled adipocytes (Figure 4(b)). In contrast, treatment of DM-cultured cells with 20, 50, or 100 µM allyl isothiocyanate resulted in concentration-dependent reduction of the quantities of Oil Red O-stained cells (Figure 3(b)) and in, respectively, 59%, 74%, and 83% reductions in lipid-filled adipocytes (Figure 4(c)). These rates were slightly lower than those observed in the cells treated with sulforaphane, at approximately 10 times the concentration.

(a)

(b)

(a)

(b)

(c)

3.2. Effect of Sulforaphane and Allyl Isothiocyanate on PPARγ and C/Ebpα mRNA Expression Levels

As shown in Figure 5, the DM-cultured cells exhibited markedly higher PPARγ and C/EBPα mRNA expression levels than the control cells, and the PPARγ and C/EBPα mRNA expression levels were significantly () suppressed by the addition of sulforaphane (Figures 5(a) and 5(b)) or allyl isothiocyanate (Figures 5(c) and 5(d)). Exposure to sulforaphane at concentrations of 5 and 10 µM reduced PPARγ mRNA expression levels by 45% and 80%, respectively, and C/EBPα mRNA expression levels by 65% and 81%, respectively. Exposure to allyl isothiocyanate at concentrations of 50 and 100 µM reduced PPARγ mRNA expression levels by 57% and 85%, respectively, and C/EBPα mRNA expression levels by 75% and 94%, respectively. Thus, sulforaphane had a similar inhibitory effect on C/EBPα and PPARγ mRNA expression levels as allyl isothiocyanate, at a 10-fold lower concentration.

(a)

(b)

(c)

(d)

3.3. Effect of Sulforaphane and Allyl Isothiocyanate on PPARγ Protein Levels

As shown in Figure 6, the DM-cultured cells exhibited markedly higher PPARγ protein levels than the control cells. PPARγ protein levels were significantly () suppressed by the addition of sulforaphane (Figures 6(a) and 6(b)). Exposure to 5 and 10 µM concentrations of sulforaphane reduced PPARγ protein levels by 59% and 87%, respectively (Figure 6(b)), while exposure to 100 µM allyl isothiocyanate produced an 80% reduction (Figure 6(d)).

(a)

(b)

(c)

(d)

4. Discussion

The results of the present study clearly showed that while both sulforaphane and allyl isothiocyanate inhibited adipocyte differentiation, sulforaphane was a much stronger inhibitor. This suggests that the anti-obesity effect of sulforaphane is greater than that of allyl isothiocyanate. Furthermore, we demonstrated that the effects of both sulforaphane and ally isothiocyanate were associated with the suppression of mRNA expression levels, leading to the downregulation of PPARγ protein levels.

The mechanism by which sulforaphane inhibits adipocyte differentiation more strongly than allyl isothiocyanate is unclear. Adipogenesis is correlated with various signaling pathways, such as insulin signaling and the PPAR regulation pathway, which are promising drug targets for obesity and metabolic disease treatment [17, 18]. The insulin receptor (IR) catalytic ability is dependent on IR expression levels and IR substrate 1 (IRS-1) tyrosine phosphorylation. IR signaling leads to serine/threonine protein kinase B (Akt/PKB) activation, which subsequently activates the C/EBPα-PPARγ pathway. PPARγ functions as a master regulator of adipocyte differentiation, whereas C/EBPα works with PPARγ to induce adipocyte differentiation. Nuclear factor erythroid factor 2 (Nrf2) activators have been shown to improve insulin signaling and decrease adipose differentiation through multiple mechanisms [19]. However, Ernst et al. [9] reported that treatment with sulforaphane and other ITCs, such as allyl isothiocyanate, results in comparative levels of phase 2 enzymes including γ-glutamyl cysteine synthetase and antioxidant enzymes via an Nrf2-dependent signal transduction pathway in cultured cells and in vivo experiments. Conversely, Valli et al. [10] and Xu et al. [11] demonstrated that sulforaphane-treated obese mice exhibited significantly increased IRS-1 protein levels and marked Akt/PKB activation. Comparison of IRS-1 upregulation by sulforaphane and other ITCs, including allyl isothiocyanate, will require additional investigation. Most importantly, the difference in the mechanism of action of the two compounds in inhibiting adipogenesis not only is the difference in the expression of C/EBPα and PPARγ but also requires further research.

The logP, or the water and n-octanol partition coefficient, is 0.23 ± 0.39 for sulforaphane and 1.77 ± 0.30 for allyl isothiocyanate [20], indicating that sulforaphane is more hydrophilic than allyl isothiocyanate. This is likely due to differences in the physicochemical properties of the side chains, excluding the ITC group [7, 8], and indicates that the nonspecific passage of sulforaphane into the cell is less favorable than that of allyl isothiocyanate; instead, sulforaphane may bind specifically to certain proteins expressed on the cell surface. Research on membrane proteins that bind specifically to sulforaphane may yield additional clarity.

5. Conclusion

Sulforaphane, a potent antioxidant derived from glucosinolates in cruciferous vegetables, has been identified as a promising chemopreventive agent to combat cancer [21–23]. Of course, the present in vitro results using 3T3-L1 cells may or may not be replicated in vivo. However, the results of this study suggest that, in addition to its known bioactivity, sulforaphane may contribute to the prevention of lifestyle-related diseases by conferring a protective effect against obesity. Our future plans include investigating sulforaphane’s mechanism of action by examining its structure-activity relationship, as well as studying the medicinal effects of its derivatives, which we hope will contribute to the discovery of preventive treatments for obesity and lifestyle-related diseases to further the maintenance and promotion of health.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Acknowledgments

This work was funded by the Osaka Medical and Pharmaceutical University.

References

P. Hossain, B. Kawar, and M. El Nahas, “Obesity and diabetes in the developing world—a growing challenge,” New England Journal of Medicine, vol. 356, no. 3, pp. 213–215, 2007.
View at: Publisher Site | Google Scholar
M. M. Mello, D. M. Studdert, and T. A. Brennan, “Obesity—the new frontier of public health law,” New England Journal of Medicine, vol. 354, no. 24, pp. 2601–2610, 2006.
View at: Publisher Site | Google Scholar
S. de Ferranti and D. Mozaffarian, “The perfect storm: obesity, adipocyte dysfunction, and metabolic consequences,” Clinical Chemistry, vol. 54, no. 6, pp. 945–955, 2008.
View at: Publisher Site | Google Scholar
P. G. Kopelman, “Obesity as a medical problem,” Nature, vol. 404, no. 6778, pp. 635–643, 2000.
View at: Publisher Site | Google Scholar
G. Kumar, H. S. Tuli, S. Mittal, J. K. Shandilya, A. Tiwari, and S. S. Sandhu, “Isothiocyanates: a class of bioactive metabolites with chemopreventive potential,” Tumor Biology, vol. 36, no. 6, pp. 4005–4016, 2015.
View at: Publisher Site | Google Scholar
R. Mithen and E. Ho, “Isothiocyanates for human health,” Molecular Nutrition & Food Research, vol. 62, no. 18, Article ID 1870079, 2018.
View at: Publisher Site | Google Scholar
L. Drobnica, P. Kristián, and J. Augustín, “The chemistry of the-NCS group,” in Cyanates and Their Thio Derivatives, S. Patai, Ed., vol. 3, pp. 1003–1221, John Wiley & Sons, Chichester, UK, 1977.
View at: Google Scholar
L. Drobnica, J. Augustin, and P. Nemec, “Lipophilicity of isothiocyanates as a criterion of their antimicrobial spectrum,” Experientia Supplementum, vol. 23, pp. 65–77, 1976.
View at: Publisher Site | Google Scholar
I. M. A. Ernst, A. E. Wagner, C. Schuemann et al., “Allyl-, butyl- and phenylethyl-isothiocyanate activate Nrf2 in cultured fibroblasts,” Pharmacological Research, vol. 63, no. 3, pp. 233–240, 2011.
View at: Publisher Site | Google Scholar
V. Valli, K. Heilmann, F. Fanesi, A. Bordoni, and C. Gerhauser, “Modulation of adipocyte differentiation and proadipogenic gene expression by sulforaphane, genistein, and docosahexaenoic acid as a first step to counteract obesity,” Oxidative Medicine and Cellular Longevity, vol. 2018, Article ID 1617202, 8 pages, 2018.
View at: Publisher Site | Google Scholar
Y. Xu, J.-F. Fu, J.-H. Chen et al., “Sulforaphane ameliorates glucose intolerance in obese mice via the upregulation of the insulin signaling pathway,” Food & Function, vol. 9, no. 9, pp. 4695–4701, 2018.
View at: Publisher Site | Google Scholar
S. Sakuma, Y. Nishioka, R. Imanishi et al., “cis9, trans11-conjugated linoleic acid differentiates mouse 3T3-L1 preadipocytes into mature small adipocytes through induction of peroxisome proliferator-activated receptor,” Journal of Clinical Biochemistry & Nutrition, vol. 47, no. 2, pp. 167–173, 2010.
View at: Publisher Site | Google Scholar
S. Sakuma, J. Fujisawa, M. Sumida et al., “The involvement of mitogen-activated protein kinases in the 1, 25-dihydroxy-cholecalciferol-induced inhibition of adipocyte differentiation in vitro,” Journal of Nutritional Science & Vitaminology, vol. 58, no. 1, pp. 1–8, 2012.
View at: Publisher Site | Google Scholar
S. Sakuma, M. Sumida, Y. Endoh et al., “Curcumin inhibits adipogenesis induced by benzyl butyl phthalate in 3T3-L1 cells,” Toxicology and Applied Pharmacology, vol. 329, pp. 158–164, 2017.
View at: Publisher Site | Google Scholar
V. Sottile and K. Seuwen, “Bone morphogenetic protein-2 stimulates adipogenic differentiation of mesenchymal precursor cells in synergy with BRL 49653 (rosiglitazone),” FEBS Letters, vol. 475, no. 3, pp. 201–204, 2000.
View at: Publisher Site | Google Scholar
M. Schubert, S. Becher, M. Wallert et al., “The peroxisome proliferator-activated receptor (PPAR)-γAntagonist 2-chloro-5-nitro-N-phenylbenzamide (GW9662) triggers perilipin 2 expression via PPARδ and induces lipogenesis and triglyceride accumulation in human THP-1 macrophages,” Molecular Pharmacology, vol. 97, no. 3, pp. 212–225, 2020.
View at: Publisher Site | Google Scholar
Y. Jia, C. Wu, J. Kim, B. Kim, and S. J. Lee, “Astaxanthin reduces hepatic lipid accumulations in high-fat-fed C57BL/6J mice via activation of peroxisome proliferator-activated receptor (PPAR) alpha and inhibition of PPAR gamma and Akt,” The Journal of nutritional biochemistry, vol. 28, pp. 9–18, 2016.
View at: Publisher Site | Google Scholar
A. Shehzad, S. Khan, and Y. Sup Lee, “Curcumin molecular targets in obesity and obesity-related cancers,” Future Oncology, vol. 8, no. 2, pp. 179–190, 2012.
View at: Publisher Site | Google Scholar
Z. Zhang, S. Zhou, X. Jiang et al., “The role of the Nrf2/Keap1 pathway in obesity and metabolic syndrome,” Reviews in Endocrine & Metabolic Disorders, vol. 16, no. 1, pp. 35–45, 2015.
View at: Publisher Site | Google Scholar
S. Kontar, D. Imrichova, A. Bertova et al., “Cell death effects induced by sulforaphane and allyl isothiocyanate on P-glycoprotein positive and negative variants in L1210 cells,” Molecules, vol. 25, no. 9, pp. 2093–2113, 2020.
View at: Publisher Site | Google Scholar
A. T. Dinkova-Kostova, W. D. Holtzclaw, R. N. Cole et al., “Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants,” Proceedings of the National Academy of Sciences, vol. 99, no. 18, pp. 11908–11913, 2002.
View at: Publisher Site | Google Scholar
M. Lenzi, C. Fimognari, and P. Hrelia, “Sulforaphane as a promising molecule for fighting cancer,” Mutation Research, vol. 635, no. 2-3, pp. 90–104, 2007.
View at: Google Scholar
A. T. Dinkova-Kostova and R. V. Kostov, “Glucosinolates and isothiocyanates in health and disease,” Trends in Molecular Medicine, vol. 18, no. 6, pp. 337–347, 2012.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2022 Satoru Sakuma et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

564

Downloads

677

Citations